Article in Science advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
29 authors.
Pierre-Antoine SoretSorbonne Université, INSERM, Centre de Recherche Saint-Antoine, CRSA, F-75012 Paris, France.ORCID 0009-0006-7808-906X
Virginie SteunouSorbonne Université, INSERM, Centre de Recherche Saint-Antoine, CRSA, F-75012 Paris, France.ORCID 0000-0002-8239-9195
Julien HedouSorbonne Université, INSERM, Centre de Recherche Saint-Antoine, CRSA, F-75012 Paris, France.ORCID 0000-0003-4721-4797
Juliette TokgozogluSorbonne Université, INSERM, Centre de Recherche Saint-Antoine, CRSA, F-75012 Paris, France.
Valeria PistorioSorbonne Université, INSERM, Centre de Recherche Saint-Antoine, CRSA, F-75012 Paris, France.ORCID 0000-0001-7624-9660
Amine MajdiINSERM, Equipe Labellisee Ligue Contre le Cancer, Centre de Recherche des Cordeliers, Sorbonne Universite, Universite Paris Cite, Paris, France.ORCID 0009-0006-4692-1093
Nadia DarwaneSorbonne Université, INSERM, Centre de Recherche Saint-Antoine, CRSA, F-75012 Paris, France.ORCID 0009-0001-3343-1494
Jean-Louis DelaunaySorbonne Université, INSERM, Centre de Recherche Saint-Antoine, CRSA, F-75012 Paris, France.ORCID 0000-0002-6512-5483
Siham BenyahiaSorbonne Université, INSERM, Centre de Recherche Saint-Antoine, CRSA, F-75012 Paris, France.ORCID 0009-0007-3562-586X
Laetitia DinardSorbonne Université, INSERM, Centre de Recherche Saint-Antoine, CRSA, F-75012 Paris, France.
Tatiana LedentSorbonne Université, INSERM, Centre de Recherche Saint-Antoine, CRSA, F-75012 Paris, France.ORCID 0000-0002-6988-8779
Marie LhommeFoundation for Innovation in Cardiometabolism And Nutrition, IHU-ICAN, F-75013 Paris, France.ORCID 0000-0002-6335-4506
Maharajah PonnaiahFoundation for Innovation in Cardiometabolism And Nutrition, IHU-ICAN, F-75013 Paris, France.ORCID 0000-0001-7761-4228
Jérôme GalonINSERM, Equipe Labellisee Ligue Contre le Cancer, Centre de Recherche des Cordeliers, Sorbonne Universite, Universite Paris Cite, Paris, France.
Patrick SoussanSorbonne Université, INSERM, Centre de Recherche Saint-Antoine, CRSA, F-75012 Paris, France.ORCID 0000-0003-2706-7371
Lawrence SerfatySorbonne Université, INSERM, Centre de Recherche Saint-Antoine, CRSA, F-75012 Paris, France.ORCID 0000-0003-3055-5579
Christophe CorpechotSorbonne Université, INSERM, Centre de Recherche Saint-Antoine, CRSA, F-75012 Paris, France.
Chantal HoussetSorbonne Université, INSERM, Centre de Recherche Saint-Antoine, CRSA, F-75012 Paris, France.ORCID 0000-0001-6469-0651
Tounsia Aït-SlimaneSorbonne Université, INSERM, Centre de Recherche Saint-Antoine, CRSA, F-75012 Paris, France.ORCID 0000-0002-7459-859X
Franck VerdonkSorbonne Université, INSERM, Centre de Recherche Saint-Antoine, CRSA, F-75012 Paris, France.ORCID 0000-0001-7061-5594
Olivier ChazouillèresSorbonne Université, INSERM, Centre de Recherche Saint-Antoine, CRSA, F-75012 Paris, France.
Dominique WendumSorbonne Université, INSERM, Centre de Recherche Saint-Antoine, CRSA, F-75012 Paris, France.
Vlad RatziuFoundation for Innovation in Cardiometabolism And Nutrition, IHU-ICAN, F-75013 Paris, France.ORCID 0000-0002-6865-3791
Sara LemoinneSorbonne Université, INSERM, Centre de Recherche Saint-Antoine, CRSA, F-75012 Paris, France.
Axelle CadoretSorbonne Université, INSERM, Centre de Recherche Saint-Antoine, CRSA, F-75012 Paris, France.ORCID 0000-0002-4283-6864
Nicolas ChignardSorbonne Université, INSERM, Centre de Recherche Saint-Antoine, CRSA, F-75012 Paris, France.ORCID 0000-0002-2680-1864
Jérémie GautheronSorbonne Université, INSERM, Centre de Recherche Saint-Antoine, CRSA, F-75012 Paris, France.ORCID 0000-0002-7727-9893
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease with no effective curative therapies. Necroptosis, a regulated necrotic cell death pathway controlled by receptor-interacting protein kinase 1 (RIPK1), has emerged as a potential driver of inflammation and fibrosis in chronic liver disorders. We investigated the role of necroptosis in PSC and whether RIPK1 inhibition could modify disease course and progression. Spatial profiling of human PSC biopsies revealed that necroptosis primarily affects cholangiocytes, while apoptosis was more frequent in hepatocytes and nonbiliary cells. In vitro, necroptosis inhibition protected cholangiocytes, and
Indexed as
Cholangitis, SclerosingReceptor-Interacting Protein Serine-Threonine KinasesAnimalsApoptosisDisease Models, AnimalFibrosisHumansMaleMiceNecroptosisReceptor-Interacting Protein Serine-Threonine KinasesRIPK1 protein, humanRipk1 protein, mouse
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
RIPK1 inhibition reduces biliary injury and fibrosis in primary sclerosing cholangitis. · full record | Socratic